4.7 Review

Contributions of Myosin Light Chain Kinase to Regulation of Epithelial Paracellular Permeability and Mucosal Homeostasis

期刊

出版社

MDPI
DOI: 10.3390/ijms21030993

关键词

tight junction; barrier function; inflammatory bowel disease; drug development; mucosal immunology; cytokines; ZO-1; occludin; claudin; actomyosin

资金

  1. National Natural Science Foundation of China [31971062]
  2. Natural Science Foundation of Jiangsu Province [BK20190043]
  3. Natural Science Foundation of the Jiangsu Higher Education Institutions of China [19KJB320003]
  4. Soochow University
  5. Research Fund of State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University [KF-GN-202004]
  6. National Institute of Diabetes Digestive and Kidney Disease [R01DK61931, R01DK068271, R24DK099803, R43DK123904]
  7. Harvard Digestive Disease Center [P30DK034854]

向作者/读者索取更多资源

Intestinal barrier function is required for the maintenance of mucosal homeostasis. Barrier dysfunction is thought to promote progression of both intestinal and systemic diseases. In many cases, this barrier loss reflects increased permeability of the paracellular tight junction as a consequence of myosin light chain kinase (MLCK) activation and myosin II regulatory light chain (MLC) phosphorylation. Although some details about MLCK activation remain to be defined, it is clear that this triggers perijunctional actomyosin ring (PAMR) contraction that leads to molecular reorganization of tight junction structure and composition, including occludin endocytosis. In disease states, this process can be triggered by pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF), interleukin-1 beta (IL-1 beta), and several related molecules. Of these, TNF has been studied in the greatest detail and is known to activate long MLCK transcription, expression, enzymatic activity, and recruitment to the PAMR. Unfortunately, toxicities associated with inhibition of MLCK expression or enzymatic activity make these unsuitable as therapeutic targets. Recent work has, however, identified a small molecule that prevents MLCK1 recruitment to the PAMR without inhibiting enzymatic function. This small molecule, termed Divertin, restores barrier function after TNF-induced barrier loss and prevents disease progression in experimental chronic inflammatory bowel disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据